ABL102 / ABL Bio - LARVOL DELTA

ABL Bio presents ABL103 and ABL102 posters at PEGS Europe [Google translation] (ABL Bio Press Release) - "ABL Bio...as a poster at the 15th Protein & Antibody Engineering Summit (PEGS Europe)...At this event, ABL Bio will disclose the anticancer effect of ABL103 according to the level of B7-H4 expression and non-clinical data analyzing B7-H4 expression in various cancer types. Based on these data, we plan to emphasize that ABL103 can be an effective treatment for breast and ovarian cancer, including triple negative breast cancer (TNBC)....At the same time, ABL Bio also discloses non-clinical data on ABL102, a dual antibody targeting ROR1 and 4-1BB, through a poster. ABL102 has the characteristic of enhancing T cell activity by inducing a decrease in regulatory T cells (Treg) in tumors, which limit T cell responses. The ABL102 poster will also be introduced in a separate oral presentation session."

Preclinical • Breast Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer

ROR1 targeted 4-1BB costimulatory bispecific antibody, ABL102, exhibits potent in vitro and vivo antitumor activity and superior safety profile (AACR 2023) - "In conclusion, ABL102 exhibited potent in vitro and vivo anti-tumor activity and it was well tolerated and safe in the NHP toxicity study. These results strongly suggest that ABL102 is promising therapeutics for ROR1 positive cancer patients."

Preclinical • Oncology • Solid Tumor • IFNG • ROR1

"K-Bio, pre-clinical presentation at AACR… targeting the global market" (HIT News) - "ABL Bio will present the preclinical data of ABL102 (ROR1x4-1BB), a candidate for immuno-anticancer drug, as a poster at the American Association for Cancer Research (AACR)....Medpacto...announced that the preclinical data of Vactosertib combination therapy for pancreatic cancer was adopted as a poster at the American Association for Cancer Research (AACR 2023). Medpacto will disclose preclinical data of the combination therapy of Vactosertib and T1-44, a protein activity inhibitor of arginine methyltransferase 5 (PRMT5), in this conference. PRMT5 protein, known as an enzyme that promotes cancer growth, is known to increase its expression in various cancers including pancreatic cancer."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor